Evidence map›Paper›PMID 29787357›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.

Dirk De Ruysscher, Anne-Marie C Dingemans, John Praag, Jose Belderbos, Caroline Tissing-Tan, Judith Herder, Tjeerd Haitjema, Fred Ubbels, Frank Lagerwaard, Sherif Y El Sharouni and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00835471 (A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC), which is not on this map. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00835471 phase2completednot on this map

A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study)

TypeinterventionalSponsorDutch Society of Physicians for Pulmonology and TuberculosisRan2009 to 2019Enrolled195ConditionsCarcinoma, Non-Small-Cell LungArmserlotinib plus docetaxel or pemetrexed, erlotinib
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Progress in radiotherapy for small-cell lung cancer.Precision radiation oncology · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. [Research Progress on Risk Factors of Brain Metastasis in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Dirk De RuysscherDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Anne-Marie C DingemansDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
John PraagDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Jose BelderbosDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Caroline Tissing-TanDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Judith HerderDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Tjeerd HaitjemaDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Fred UbbelsDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Frank LagerwaardDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Sherif Y El SharouniDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Jos A StigtDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Egbert SmitDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Harm van TinterenDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Vincent van der NoortDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.
Harry J M GroenDirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging-were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy with or without surgery. The primary end point-development of symptomatic brain metastases at 24 months-was defined as one or a combination of key symptoms that suggest brain metastases-signs of increased intracranial pressure, headache, nausea and vomiting, cognitive or affective disturbances, seizures, and focal neurologic symptoms-and magnetic resonance imaging or computed tomography demonstrating the existence of brain metastasis. Adverse effects, survival, quality of life, quality-adjusted survival, and health care costs were secondary end points. Results Between 2009 and 2015, 175 patients were randomly assigned: 87 received PCI and 88 underwent observation only. Median follow-up was 48.5 months (95% CI, 39 to 54 months). Six (7.0%) of 86 patients in the PCI group and 24 (27.2%) of 88 patients in the control group had symptomatic brain metastases ( P = .001). PCI significantly increased the time to develop symptomatic brain metastases (hazard ratio, 0.23; [95% CI, 0.09 to 0.56]; P = .0012). Median time to develop brain metastases was not reached in either arm. Overall survival was not significantly different between both arms. Grade 1 and 2 memory impairment (26 of 86 v seven of 88 patients) and cognitive disturbance (16 of 86 v three of 88 patients) were significantly increased in the PCI arm. Quality of life was only decreased 3 months post-PCI and was similar to the observation arm thereafter. Conclusion PCI significantly decreased the proportion of patients who developed symptomatic brain metastases with an increase of low-grade toxicity.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungCranial IrradiationFemaleHumansLung NeoplasmsMaleNeoplasm StagingProgression-Free SurvivalQuality of LifeSurvival Rate

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.